Method for psychomotor action speed increase with anxiolytic afobazol

FIELD: medicine.

SUBSTANCE: improving the psychomotor action in individuals suffering from mild and moderate anxiodepressive disorders is ensured by prescribing anxiolytic afobazol in a daily dose of 30-60 mg divided in three times throughout the day. The therapeutic course makes 14 days.

EFFECT: invention provides higher speed of hand-eye reactions accompanied by reduced responsiveness to a visual signal.

1 tbl

 

The invention relates to medicine, namely, clinical pharmacology, and can be used to improve hand-eye reactions in patients suffering from anxiety-depressive syndrome.

The urgency of development of this method is the need to improve hand-eye reactions in workers rail, road and other transport modes to save professionally significant psychophysiological functions.

A known way of drug use blood as a means of prevention and correction of movement disorders, extrapyramidal disorders (Seredenin S.B., Voronina T.A., Garibova TL patent No. 2421222 C2 "means for the prevention and correction of movement disorders, extrapyramidal disorders caused by antipsychotic drugs"). The disadvantage of this method is the use of the drug Afobazol in patients taking medicinal doses without monitoring of psychophysiological functions, namely the speed of visual-motor reactions.

There is a method of correction of psychophysiological state of a person (Konstantinov C.V., Sizov V., Miroshnikov B. (application for invention 94005928/14, 15.02.1994), in which the recorded signals on the electroencephalogram (EEG) is converted into sound signals, and then affect the individual by the organization Biol the environmental acoustic feedback (BAOS). While the transposition of the spectrum of the EEG signals in the frequency range of the sound signals is carried out by decomposition of EEG signals in a series of quasi-periodic signals using comb filters and recording periods of the received EEG signals with subsequent accelerated reading and add last. The disadvantage of this method is the complexity of implementation using methods that require special equipment.

Technical result: development of a method of increasing the speed of psychomotor reactions in patients suffering from anxiety-depressive syndrome, by use of the drug effects.

A prerequisite to the development of this method was the observation of patients admitted for examination and treatment on an acute exacerbation of chronic pancreatitis in the gastroenterological Department of the railway clinical hospital at the station Voronezh-1 JSC "RZD". When examining this group of patients, with 61.3% of patients when talking with the use of specialized scales and questionnaires revealed signs of anxiety and depressive disorders mild to moderate severity. Control of psychophysiological functions to define the time of simple motor responses (da), complex motor reaction (SDR), the response to a moving object (WFD). In the study of simple motor reacts the determined average response time for the red signal (da, MS). Complex motor reaction were analysed by the average reaction time to the green light (SDR TCP. green., MS) and red light (SDR TCP. CR., MS). Evaluation of the reaction rate on the moving object was carried out according to the average value of the time lag (WFD TCP. square, MS).

All patients who had showed signs of anxiety and depressive disorders, was appointed psychotropic therapy - tranquilizer adaptol or anxiolytic afobazole. Under supervision there were 44 people aged 22 to 64 years old. Depending on the treatment the patients were divided into two groups. The first group consisted of 22 patients, who were assigned anxiolytic afobazole in therapeutic daily dose of 30-60 mg, divided into 3 doses during the day. Therapy with this drug was 14 days. Patients of the second group, in the amount of 22 people received tranquilizer adaptol in a daily dose of 1000-1500 mg, divided into 2-3 doses. The course of therapy is 14 days. The control group consisted of 24 patients who had shown signs of anxiety and/or depression.

Monitoring the status of the psychophysiological functions before therapy showed a significant increase in the time a simple motor reaction, complex motor responses and reactions to a moving object in patients first and second groups suffering from anxiety-de is resignin syndrome (table 1), testified to the inhibition of visual-motor function in individuals with affective disorders.

Table 1

The performance of visual-motor reactions in patients with anxiety-depressive syndrome

IndexThe follow-up periodControl group (n=24)1st group of patients who adaptol (n=22)The 2nd group of patients who afobazole (n=22)
Da, MSbefore the treatment350,8±12,3501,2±3,32568,5±7,3
Day 7301±9,5548,7±6,5403, 2±10,4*
14th day296,7±11,5614,25±12,9325,9±8,9*
SDR Dresel, MSbefore the treatment453,5±7,8697,5±5,8760,7±4,5
Day 7428,7±4,5728,6±3,9 656,9±3,9*
14th day450,2±8,6679,5±5,6501,5±7,7**
SDR Tsrc, MSbefore the treatment508,7±2,2715,5±9,5706,9±8,4
Day 7463,7±9,7620,5±3,3613,9±7,2*
14th day452,2±5,6578,3±2,9572,3±3,7*
WFD Tspl, MSbefore the treatment39,5±2,774,5±6,473,25±8,8
Day 745,3±3,670,3±7,261,6±5,9
14th day41,7±3,972,2±4,453,1±7,8*

**p<0,01 - reliability of differences from baseline to the treatment of

* p<0,05 - reliability of differences from baseline to the treatment of

On a background of reception of afobazole on 6-14 day arpiiprazole speed of visual-motor reactions has improved, that was accompanied by a reduction of the time response to a visual signal when the evaluation of simple motor reaction, complex motor responses to red and green light, as well as reaction to a moving object (table 1).

When assigning tranquilizer adaptol reliable change indices of visual-motor reactions did not occur (table 1).

The data obtained indicate that the anxiolytic afobazole can improve physiological functions by increasing the speed of visual-motor reactions, which is important in workers rail, road and other modes of transport, whose professional work requires high concentration of attention and fast reaction rate.

Thus, the identified unknown in the prior art effect, namely an increase in the speed of visual-motor reactions in a limited choice of drugs among persons operator occupations, which are used for the correction of anxiety-depressive syndrome.

A way to increase the speed of psychomotor reactions in patients suffering from anxiety and depressive disorders mild to moderate severity, which consists in the appointment of afobazole in a daily dose of 30-60 mg, divided into 3 doses during the day; course of treatment is 14 days.



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula

,

wherein R1 represents H, fluoro-, chloro- or C1-2alkoxygroup optionally substituted by one or more fluoro group; A represents O or S; R2 and R3 independently represent H or chloro; provided R2 and R3 are not positioned in relation to each other; R4 and R5 independently represent H or C1-4alkyl group; while X and Y independently represent O or CH2, provided X and Y are different. The invention also refers to a pharmaceutical composition possessing an antagonist activity in relation to type 1 melanin-concentrating hormone (MCH1) receptor and type 3 histamine receptor (H3) containing the compounds of formula I, a method of treating or preventing and to usage of the compounds of formula I.

EFFECT: compounds of formula I as type 1 melanin-concentrating hormone (MCH1) receptor and type 3 histamine receptor (H3) antagonists.

14 cl, 1 tbl, 2 dwg, 10 ex

FIELD: medicine.

SUBSTANCE: invention concerns an anxiolytic representing the amino acid glycine immobilised on the detonation-synthesised nanodiamond particles of 2-10 nm in size, and a method for preparing it.

EFFECT: improving properties.

4 cl, 7 dwg, 6 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: claimed is application of potassium salt 2-[1-(1,1-dioxothietanyl-3)benz-imidazolyl-2-thio]acetic acid (known as immunomodulator) as medication, possessing anxiolytic action. It is demonstrated that action of claimed medication on different anxiety components is comparable with effect of standard anxiolytics phenazepam and afobazole, but it is not accompanied by myorelaxant action characteristic of benzodiasepin anxiolytics (phenazepam).

EFFECT: improvement of composition efficiency.

2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (1), having affinity to the µ-opioid receptor and the to the ORL1 receptor, a medicinal agent containing said compounds and use thereof to obtain a medicinal agent for treating pain and other diseases. In general formula (1), Y1, Y1', Y2, Y2', Y3, Y3', Y4 and Y4' denote -H; R1 and R2 independently denote -CH3; R3 denotes R0, where R0 denotes C1-8-alkyl; aryl, selected from phenyl which is unsubstituted or mono-substituted with -F, -Cl, -Br, -I, -CN or -OR0, where R0 denotes -C1-3-alkyl; unsubstituted heteroaryl, selected from a 5-member heteroaryl with one S atom as a heteroatom; R4 denotes R0, where R0 denotes aryl, selected from phenyl which is unsubstituted or mono-substituted with -F, -Cl, -Br, -I, -CN or -OR0, where R0 denotes -C1-3-alkyl; 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indolyl, mono-substituted with -S(O)2-phenyl; unsubstituted -dihydroisoindolyl or unsubstituted -indolyl; or R4 denotes -OR0 or -SR0, where R0 denotes a cycloaliphatic group selected from -C5-6-cycloalkyl; aryl, selected from unsubstituted phenyl; C1-2-alkylaryl, where aryl denotes phenyl, which is unsubstituted or mono-substituted with -OR0, where R0 denotes -C1-3-alkyl; and R5 denotes -H or -CH3.

EFFECT: obtaining a medicinal agent for treating pain and other diseases.

7 cl, 3 tbl, 22 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel medication possessing antidepressant, anxiolytic and nootropic activity, which represents compound of general formula where: X is NH or 1,4-piperasino; R1=H or CH3; R2=H, OCH3 or N(CH3)2.

EFFECT: on experimental models in vivo compounds, possessing original spectrum of psychotropic action, exceed medications of different pharmacological groups - aphobazolum, melipramin, phenotropil, diazepam in complex of useful qualities, and can be applied in treatment of patients with anxiety and depressive disorders.

4 tbl, 8 ex

FIELD: medicine.

SUBSTANCE: what is described is N-(4-acetoxybenzoyl)glycine lithium salt of formula I: .

EFFECT: higher tranquilising and nootropic action.

4 tbl, 5 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel (3-arylsulphonyl quinolin-8-yl-dialkyl-amines of general formula 1 and pharmaceutically acceptable salts thereof, which are selective antagonists of serotonin 5-HT6 receptors. The compounds can be used as an active ingredient in pharmaceutical compositions and medicinal agents for treating diseases of the central nervous system, pathogenesis of which is associated with 5-HT6 receptors. In particular, the compounds can be used in case of neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, Huntington's disease, in anxiety or cognitive disorders and for enhancing mental capabilities. In general formula 1 , Ar is phenyl, optionally substituted in position 3 with a halogen atom, or naphthyl, R1 and R2 are an unsubstituted methyl or ethyl.

EFFECT: improved method.

10 cl, 9 dwg, 2 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely preparing an agent of hindu lotus seed extract (Nelumbo nucifera) possessing anxiolytic and antidepressive action. The agent possessing anxiolytic and antidepressive action prepared by extraction of hindu lotus seed extract (Nelumbo nucifera) in 50% ethanol in a Soxhlet extraction apparatus in the specific proportions.

EFFECT: agent possess the effective anxiolytic and antidepressive action.

3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention provides new imidazo[1,2-b]pyridazine compounds covered by general structural formula (I) wherein the radicals and symbols have the values presented in the patent claim, and pharmaceutically acceptable salts thereof. The compounds of structural formula (I) are effective both for treating or preventing the diseases related to GABA receptor inhibition, anxiety, epilepsy, sleep disorders, including insomnia, and for inducing a sedative-hypnotic, anaesthetic effect, sleep and muscle relaxation.

EFFECT: there are presented methods for preparing the above compounds, and also intermediate compounds for preparing them.

21 cl, 4 tbl, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) and salts thereof wherein R1 represents -A11-A12-; R2 represents tetrahydrofurylmethyl, tetrahydropyranylmethyl or tetrahydropyranyl; A11 represents a single bond, methylene or 3,2-ethylene; A12 represents C1-6 alkyl, C3-6 cycloalkyl or C3-6 cycloalkyl containing methyl; R3 represents methoxy, cyano, cyclobutyloxymethyl, methoxymethyl or ethoxymethyl; and R4 represents methoxy or chlorine. Also, the invention also refers to a pharmaceutical composition possessing corticotrophin-releasing factor (CRF) receptor antagonist activity, containing a compound of formula (I), to a therapeutic/preventive agent, and a method of treating the diseases specified in the patent claim.

EFFECT: there are presented the compounds of formula (I) as corticotropin-releasing factor (CRF) receptor antagonists.

20 cl, 2 dwg, 2 tbl, 51 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutics, namely to a stable pharmaceutical composition of nanostructured telmisartan for treating hypertension, containing nanostructured telmisartan having an average particle size less than approximately 600 nm, and at least one stabilising agent specified in a group of sodium dodecyl sulphate and polyvinyl pyrrolidone, wherein the composition in prepared in a continuous flow reactor, preferentially in a microfluidics continuous flow reactor, as well as to a method for preparing the composition and using it.

EFFECT: invention provides better physical-chemical characteristics and pharmacokinetics of the active principle.

11 cl, 9 ex, 3 tbl, 14 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to pharmaceutics and medicine and use of tricyclic imidazo[1,2-a]benzimidazole derivatives of general formula I or 1,3-disubstituted 2-aminobenzimidazolium halides of general formula II as an agent having cardioprotective action with high efficiency.

EFFECT: high efficiency.

3 cl, 1 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a pharmaceutical composition of 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole, as well as to using it in producing a drug for treating C. Difficile-associated diarrhoea (CDAD) by selective bacteriostatic and/or bactericidal activity on Clostridium difficile as compared to C. perfringens, Staphylococcus aureus, Enterococcus faecium, Enterococcus faecalis, Bacillus subtilis and Bacteroides fragilis.

EFFECT: what is prepared is the new pharmaceutical composition possessing effective biological properties.

2 cl, 8 tbl, 8 ex

FIELD: chemistry.

SUBSTANCE: invention relates to encapsulation, particularly a method of producing fenbendazole microcapsules in a sodium carboxymethyl cellulose capsule. The method involves dissolving fenbendazole in dioxane or dimethyl sulphoxide or dimethyl formamide, adding the obtained fenbendazole solution to the solution of sodium carboxymethyl cellulose in dioxane in the presence of surfactant E472s while stirring at a rate of 1000 rps. Fenbendazole and sodium carboxymethyl cellulose are taken in weight ratio of 1:3. Methyl carbinol and distilled water, taken in ratio of 2:1 vol/vol, are then added. The obtained suspension of microcapsules is filtered and dried. The process is carried out at 25°C for 20 minutes without special equipment.

EFFECT: invention simplifies and speeds up the process of producing microcapsules, reduces losses during production thereof (high mass output).

3 ex

FIELD: chemistry.

SUBSTANCE: fenbendazole is dissolved in dioxane or dimethyl sulphoxide or dimethyl formamide. The obtained fenbendazole solution is added to a solution of sodium carboxymethyl cellulose in ethyl acetate in the presence of an E472s preparation while stirring at a rate of 1000 rps, wherein the fenbendazole and sodium carboxymethyl cellulose are taken in weight ratio of 1:3. Methyl carbinol and distilled water, taken in volume ratio of 2:1, respectively, are then added. The obtained suspension of microcapsules is filtered and dried. The process of producing fenbendazole microcapsules carried out at 25°C for 20 minutes without special equipment.

EFFECT: improved method.

3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of pharmaceutics, in particular, to obtaining fenbendazole capsules. In realisation of a method simplification and acceleration of the process of obtaining microcapsules, reduction of loss in the process of obtaining microcapsules (increase of the output by weight) are ensured.

EFFECT: claimed method is characterised by application of sodium carboxymethylcellulose as an envelope of microcapsules, fenbendazole as their core, as well as application of two precipitants - butanol and dioxane.

3 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to pharmacology, namely to use of bromide 2-benzyl-1-morpholinoethyl-3-pivaloylmethylbenzimidazole of formula I as the cardiotonic active compound, including for production of the cardiotonic preparation.

EFFECT: increasing cardiotonic activity.

2 cl, 6 dwg, 5 tbl

FIELD: chemistry.

SUBSTANCE: claimed is application of potassium salt 2-[1-(1,1-dioxothietanyl-3)benz-imidazolyl-2-thio]acetic acid (known as immunomodulator) as medication, possessing anxiolytic action. It is demonstrated that action of claimed medication on different anxiety components is comparable with effect of standard anxiolytics phenazepam and afobazole, but it is not accompanied by myorelaxant action characteristic of benzodiasepin anxiolytics (phenazepam).

EFFECT: improvement of composition efficiency.

2 tbl

FIELD: chemistry.

SUBSTANCE: claimed invention relates to novel compound of formula (1) or its pharmaceutically acceptable salt, possessing SNS inhibiting properties. In general formula R1 represents (1) hydrogen atom, (2) halogen atom, (3) C1-6alkyl group or (4) C1-6halogenalkyl group (whereR1 can be present in any substitutable position of benzene or pyridine ring); L represents (1) simple bond, (2) -O- or (3) -CH2O- (where L can be present in position 5 or 6 of condensed cycle); R2 represents (1) C6-10aryl group (C6-10aryl group is optionally condensed with C3-6cycloalkane), optionally substituted with substituent(s), X represents carbon atom or nitrogen atom. Other values of radicals are given in the invention formula.

EFFECT: obtaining compounds which can be used to prepare medication for treatment or prevention of such diseases as neuropathic pain, nociceptive pain, dysuria, disseminated sclerosis, etc.

19 cl, 47 tbl, 237 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to a crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2.2.2]oct-5-en-2-yl isobutyric acid ester. Also, the invention refers to a pharmaceutical composition of the above crystalline salt and using the above crystalline salt for preparing the pharmaceutical composition.

EFFECT: what is prepared is the crystalline salt of (1R*,2R*,4R*)-2-(2-{[3-(4,7-dimethoxy-1H-benzoimidazol-2-yl)propyl]methylamino}ethyl)-5-phenylbicyclo[2,2,2]oct-5-en-2-yl isobutyric acid ester that can be effective as a L/T-type calcium channel blocker.

15 cl, 11 dwg, 10 tbl, 6 ex

FIELD: organic chemistry, pharmacy.

SUBSTANCE: invention relates to new derivatives of benzimidazole represented by the following formula (I) or its salt:

wherein R1 represents (lower)-alkyl group; R2 represents aromatic (lower)-alkyl group that can be substituted with one or more groups taken among halogen atom, alkyl group, halogen-(lower)-alkyl group, nitro-group, aromatic group, aromatic (lower)-alkoxy-group, (lower)-cycloalkyloxy-(lower)-alkyl group, aromatic (lower)-alkyl group, aromatic (lower)-alkenyl group, aromatic (lower)-alkynyl group, aromatic oxy-(lower)-alkyl group, (lower)-cycloalkyl-(lower)-alkoxy-group, alkenyl group, (lower)-alkoxy-group, (lower)-alkylthio-group and (lower)-alkanesulfonylcarbamoyl group; R3 represents alkyl group, hydroxy-(lower)-alkyl group, alkenyl group, aromatic group, halogenated aromatic group, (lower)-alkyl aromatic group, (lower)-alkenyl aromatic group or aromatic (lower)-alkenyl group; -X- represents cross-linking group represented by one of the following formulas: (II) , (III) , (IV) , (V) . Also, invention relates to pharmaceutical compositions eliciting activity that reduces blood glucose level based on this compound. Invention provides preparing new compounds and pharmaceutical compositions based on thereof used for prophylaxis and treatment of damaged tolerance to glucose, diabetes mellitus, insulin-resistance syndrome, vascular failures syndrome, hyperlipidemia and cardiovascular disorders.

EFFECT: valuable medicinal properties of compounds and compositions.

16 cl, 1 tbl, 86 ex

Up!